Caregen (CEO Yongji Jeong) announced on the 20th that it participated in the world's largest bio industry event, 'Bio International Convention 2025 (BIO USA 2025)' held in Boston, USA in June with a single booth and completed numerous global partnering meetings.
Since 2019, Caregen has participated in BIO USA with a single booth every year, steadily expanding opportunities for collaboration with global pharmaceutical companies and investment institutions, focusing on peptide-based platform technology. In particular, at this year’s event, key pipelines such as ▲CG-P5, a candidate for the treatment of wet macular degeneration ▲Korglutide, a GLP-1-like peptide ▲MyoKi, a muscle activating peptide, garnered attention from global partners, and discussions on technology transfer and joint development were held.
CG-P5 is a non-invasive treatment candidate that is being developed as an eye drop formulation, unlike existing injection-based treatments. It is currently in the final stages of phase 1 clinical trials in the U.S. and is awaiting submission to the FDA.
Another ophthalmic treatment candidate, CG-T1, was introduced as a dry eye treatment with a mechanism of action that is differentiated from existing cyclosporine preparations. Since it is expected to simultaneously improve inflammation and increase tear secretion, it has received joint research proposals from many global pharmaceutical companies.
Jeong Yong-ji, CEO of Caregen, said, “This BIO USA 2025 has become an important turning point for Caregen’s technology to lead to global collaboration,” and “Starting in the second half of the year, we plan to actively pursue technology transfer and joint development negotiations centered on major pipelines.”
- See more related articles
You must be logged in to post a comment.